Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683980 · ClinicalTrials.gov registry record · NA
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
A NA study of Treatment of Benign Prostatic Hyperplasia, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02683980 is a NA study of Treatment of Benign Prostatic Hyperplasia that has completed, run by Boston Scientific Corporation. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02683980, a NA study of Treatment of Benign Prostatic Hyperplasia, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device. Follow up visits are scheduled for the day of release from the hospital and at 1 and 3 months post procedure. The primary objective of this study is to explore Vaporization efficacy and safety when treating BPH (Benign prostatic hyperplasia) with the contact side firing fiber with recommended settings.
Conditions Studied
Interventions
- DEVICE Lumenis Pulse P120H and Xpeeda side firing fiber
Study Locations (1)
New York
- New York Methodist Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683980
The ClinicalTrials.gov registry entry for NCT02683980 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment of Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Lumenis Pulse P120H and Xpeeda side firing fiber is the first listed.
NCT02683980 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02683980 about?
NCT02683980 is a clinical study titled "Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH". Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device. Follow up visits are scheduled for the day of release from the hospital and at 1 and 3 months post procedure. The prim...
What is the current status of trial NCT02683980?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2016-02. Estimated completion is 2017-11-01.
What conditions does trial NCT02683980 study?
This clinical trial studies the following conditions: Treatment of Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT02683980?
The interventions under investigation include: Lumenis Pulse P120H and Xpeeda side firing fiber (DEVICE).
Who is sponsoring clinical trial NCT02683980?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02683980 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.